J L Schultze

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens
    J L Schultze
    Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, D540C, Boston, MA 02115, USA
    Vox Sang 80:81-9. 2001
  2. ncbi request reprint A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2
    J L Schultze
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 113:455-60. 2001
  3. ncbi request reprint T cell mediated immunotherapy for B cell lymphoma
    J L Schultze
    Department of Adult Oncology, Disease Center for Hematologic Malignancies, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Mol Med (Berl) 77:322-31. 1999
  4. ncbi request reprint Why do B cell lymphoma fail to elicit clinically sufficient T cell immune responses?
    J L Schultze
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School Boston, MA 02115, USA
    Leuk Lymphoma 32:223-36. 1999
  5. ncbi request reprint Vaccination as immunotherapy for B cell lymphoma
    J L Schultze
    Department of Adult Oncology, Harvard Medical School, Boston, MA 02115, USA
    Hematol Oncol 15:129-39. 1997
  6. pmc CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy
    J L Schultze
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Clin Invest 100:2757-65. 1997
  7. ncbi request reprint From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens
    J L Schultze
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Trends Immunol 22:516-23. 2001
  8. ncbi request reprint Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase
    R H Vonderheide
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 7:3343-8. 2001
  9. ncbi request reprint Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals
    R H Vonderheide
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 61:8366-70. 2001
  10. pmc Human non-germinal center B cell interleukin (IL)-12 production is primarily regulated by T cell signals CD40 ligand, interferon gamma, and IL-10: role of B cells in the maintenance of T cell responses
    J L Schultze
    Department of Adult Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Exp Med 189:1-12. 1999

Detail Information

Publications17

  1. ncbi request reprint Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens
    J L Schultze
    Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, D540C, Boston, MA 02115, USA
    Vox Sang 80:81-9. 2001
    ..We are now capable of tracking antigen-specific T cells at a single cell level. This review will analyse recent developments and highlight some important issues that need to be addressed in the future...
  2. ncbi request reprint A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2
    J L Schultze
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 113:455-60. 2001
    ....
  3. ncbi request reprint T cell mediated immunotherapy for B cell lymphoma
    J L Schultze
    Department of Adult Oncology, Disease Center for Hematologic Malignancies, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Mol Med (Berl) 77:322-31. 1999
    ..Here we discuss previous and currently explored immunotherapeutic strategies for B cell lymphoma...
  4. ncbi request reprint Why do B cell lymphoma fail to elicit clinically sufficient T cell immune responses?
    J L Schultze
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School Boston, MA 02115, USA
    Leuk Lymphoma 32:223-36. 1999
    ..Understanding these complex defects of anti-lymphoma immune responses should allow us to redefine our immunotherapeutic strategies to overcome these detects and induce clinically sufficient T cell mediated immune responses...
  5. ncbi request reprint Vaccination as immunotherapy for B cell lymphoma
    J L Schultze
    Department of Adult Oncology, Harvard Medical School, Boston, MA 02115, USA
    Hematol Oncol 15:129-39. 1997
    ..Currently explored and future vaccination strategies for B cell lymphoma will be discussed here...
  6. pmc CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy
    J L Schultze
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Clin Invest 100:2757-65. 1997
    ..We, therefore, contend that CD40-activated B cells are an alternative source of highly efficient APCs with which to generate antigen-specific T cells ex vivo for autologous adoptive immunotherapy...
  7. ncbi request reprint From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens
    J L Schultze
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Trends Immunol 22:516-23. 2001
    ..Here, we suggest that, based on these advancements, a new class of tumor Ags can be identified by directly linking cancer genomics to cancer immunology and immunotherapy...
  8. ncbi request reprint Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase
    R H Vonderheide
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 7:3343-8. 2001
    ..The applicability of hTERT as a potential target for anticancer immunotherapy would be widened by the identification of epitopes restricted to other common HLA alleles, such as HLA-A3 antigen...
  9. ncbi request reprint Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals
    R H Vonderheide
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 61:8366-70. 2001
    ..These findings support clinical efforts to target the hTERT as a tumor antigen with broad therapeutic potential...
  10. pmc Human non-germinal center B cell interleukin (IL)-12 production is primarily regulated by T cell signals CD40 ligand, interferon gamma, and IL-10: role of B cells in the maintenance of T cell responses
    J L Schultze
    Department of Adult Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Exp Med 189:1-12. 1999
    ..Furthermore, IL-12 and IL-6 might provide a positive feedback during cognate T-B interactions, thereby maintaining T cells' differentiation pattern during amplification of the immune response...
  11. ncbi request reprint CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity
    R H Vonderheide
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Int J Oncol 19:791-8. 2001
    ....
  12. ncbi request reprint The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
    R H Vonderheide
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Immunity 10:673-9. 1999
    ..These findings identify hTERT as a potentially important and widely applicable target for anticancer immunotherapeutic strategies...
  13. pmc Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients
    B Maecker
    Department of Adult Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA
    Clin Exp Immunol 141:558-62. 2005
    ..These results suggest that strategies targeting hTERT and CYP1B1 may have to utilize techniques to induce T cell responses from a naive precursor frequency...
  14. ncbi request reprint Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule
    A Trojan
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, 02114 Boston, Massachusetts, USA
    Cancer Res 61:4761-5. 2001
    ..Most important, CTL cell lines that are generated against these peptides specifically lyse epithelial tumor cells expressing Ep-CAM but not normal hematopoietic or bronchial epithelial cells...
  15. ncbi request reprint Linking genomics to immunotherapy by reverse immunology--'immunomics' in the new millennium
    B Maecker
    Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, 02115, USA
    Curr Mol Med 1:609-19. 2001
    ..Basic biological principles of 'reverse immunology' as well as technical advantages and difficulties will be addressed...
  16. ncbi request reprint Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen
    A A Cardoso
    Division of Hematologic Malignancies and Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 88:41-8. 1996
    ..Attempts to induce clinically significant antitumor immune responses may then require not only mechanisms to repair the antigen presenting capacity of the tumor cells, but also reversal of tolerance...
  17. pmc Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation
    K T Hall
    Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 93:11780-5. 1996
    ..Thus, these results suggest that semaphorins as exemplified by CD100 also play a functional role in the immune system...